Venkatarangana M.,Connexios Life science Pvt Ltd
Journal of Functional Foods | Year: 2015
Standardization is an essential step in the development of nutraceutical based formulations or products. The objective of the present study was to exemplify screening standardization of the potent antioxidant nutraceuticals (generic), namely curcumin, quercetin, hesperidin, gallic acid, citric acid, L-ascorbic acid, phytic acid and α-tocopherol based on ferric reducing antioxidant power (FRAP) value and also tried to justify the reliability of two different designs of experiments i.e. Plackett-Burman fold-over design and Taguchi L18 in screening related experiments. First screening of antioxidant nutraceutical was performed by Plackett-Burman fold-over design (resolution IV) and the outcome was analysed based on Pareto chart of standardized effect where the quercetin, gallic acid and curcumin have shown p value of <0.05 and the same factors were found to be positive outliner in half normal probability analysis. Further, the results were validated using factorial Taguchi orthogonal array, based on SN ratio (maximum the best response). Both statistical designs have given the same order of potency based on FRAP value as: quercetin > gallic acid > curcumin. Therefore it can be concluded that the statistical design of experiments is reliable in screening related experiments for development of nutraceutical formulations or products. © 2015 Elsevier Ltd. Source
Baliga M.S.,Father Muller Medical College |
Joseph N.,Father Muller Medical College |
Venkataranganna M.V.,Connexios Life science Pvt Ltd |
Saxena A.,University of South Carolina |
And 2 more authors.
Food and Function | Year: 2012
Inflammatory bowel disease (IBD) comprising of ulcerative colitis (UC) and Crohn's disease (CD) is a major ailment affecting the small and large bowel. In clinics, IBD is treated using 5-amninosalicylates, antibiotics, the steroids and immunomodulators. Unfortunately, the long term usages of these agents are associated with undue side effects and compromise the therapeutic advantage. Accordingly, there is a need for novel agents that are effective, acceptable and non toxic to humans. Preclinical studies in experimental animals have shown that curcumin, an active principle of the Indian spice turmeric (Curcuma longa Linn) is effective in preventing or ameliorating UC and inflammation. Over the last few decades there has been increasing interest in the possible role of curcumin in IBD and several studies with various experimental models of IBD have shown it to be effective in mediating the inhibitory effects by scavenging free radicals, increasing antioxidants, influencing multiple signaling pathways, especially the kinases (MAPK, ERK), inhibiting myeloperoxidase, COX-1, COX-2, LOX, TNF-α, IFN-γ, iNOS; inhibiting the transcription factor NF-κB. Clinical studies have also shown that co-administration of curcumin with conventional drugs was effective, to be well-tolerated and treated as a safe medication for maintaining remission, to prevent relapse and improve clinical activity index. Large randomized controlled clinical investigations are required to fully understand the potential of oral curcumin for treating IBD. This journal is © The Royal Society of Chemistry. Source
Connexios Life science Pvt. Ltd. | Date: 2013-12-05
The present invention relates to use of inhibitors of TAK-1 for the production of pharmaceutical agents to achieve glycemic control in mammals and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of this enzyme.
Connexios Life science Pvt. Ltd. | Date: 2013-06-19
The embodiments disclosed here in relates to use of activators of ADSL for the production of pharmaceutical agents to achieve glycemic control in mammals and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this enzyme.
CONNEXIOS LIFE science PVT. LTD. | Date: 2012-12-21
The present invention relates to certain amide derivatives that have the ability to inhibit 11--hydroxysteroid dehydrogenase type 1 (11-HSD-1) and which are therefore useful in the treatment of certain disorders that can be prevented or treated by inhibition of this enzyme. In addition the invention relates to the compounds, methods for their preparation, pharmaceutical compositions containing the compounds and the uses of these compounds in the treatment of certain disorders. It is expected that the compounds of the invention will find application in the treatment of conditions such as non-insulin dependent type 2 diabetes mellitus (NIDDM), insulin resistance, obesity, impaired fasting glucose, impaired glucose tolerance, lipid disorders such as dyslipidemia, hypertension and as well as other diseases and conditions.